Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Daratumumab for Smoldering Myeloma

December 6th 2017

KRd for High-Risk Smoldering Myeloma

December 6th 2017

AML Studies: BiTE Antibodies and Age for Transplant

December 6th 2017

AML Studies: FLT3 Inhibitors

December 6th 2017

Acute Myeloid Leukemia: Novel Targeted Therapies

December 6th 2017

NHL Studies: CAR T Therapy, Rituximab Maintenance, & PD-L1

December 6th 2017

New Data for Mantle Cell Lymphoma

December 6th 2017

Hodgkin Lymphoma: Upfront Brentuximab Vedotin + AVD

December 6th 2017

Pre-Conference Perspectives on Hematologic Malignancies

December 6th 2017

Dr. O'Connor Discusses Acalabrutinib in MCL

December 6th 2017

Owen O'Connor, MD, PhD, discusses acalabrutinib (Calquence) in mantle cell lymphoma (MCL).

Oncologist Discusses Medical Marijuana for Chronic Pain Management

December 5th 2017

Jerry W. Mitchell, MD, discusses the use of medical marijuana as a chronic pain relief for patients with hematologic malignancies ad other tumor types.

AML Field Advances With New Agents, But More Work Remains

December 5th 2017

Olga Frankfurt, MD, discusses advances in the field of AML and challenges that lie ahead.

Expert Highlights Advances in CAR T-Cell Therapy

December 5th 2017

Noelle Frey, MD, discusses the FDA approvals of CAR T-cell therapies, as well as the bright future of the treatment.

Expert Discusses Guidelines, Next Steps With MPNs

December 4th 2017

Brady L. Stein, MD, discusses the differences between the types of MPNs, the NCCN guideline changes, and the important role of JAK inhibitors.

Dr. Gordon on Clinical Trials in Hodgkin Lymphoma

December 1st 2017

Leo I. Gordon, MD, a professor of medicine at Feinberg School of Medicine, Northwestern University, discusses clinical trials in Hodgkin lymphoma.

Better Patient Selection Needed for AML Therapies

November 30th 2017

Alexander E. Perl, MD, discusses the future of FLT3 inhibitors, current obstacles with treating patients with acute myeloid leukemia, and what pivotal trial results the community can expect to hear in the coming months.

FDA Grants Mogamulizumab Priority Review for CTCL

November 28th 2017

The FDA has granted a priority review to a biologics license application for mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

Dr. Young on the Challenges of Using Anticoagulants in Children With Cancer

November 28th 2017

Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, discusses the challenges of using anticoagulants in children with cancer.

Dr. Gordon on the Role of Checkpoint Inhibitors in Hematologic Malignancies

November 21st 2017

Leo I. Gordon, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the role of checkpoint inhibitors for patients with hematologic malignancies.

Nilotinib Approved in Europe for Subset of Pediatric CML

November 21st 2017

The European Commission has approved nilotinib (Tasigna) for the treatment of pediatric patients with Ph+ chronic myeloid leukemia in the chronic phase.